What we do
Partnering with life sciences companies to bring drugs, devices and diagnostics to market
We’ve brought together top talent from across the industry
We’ve brought together top talent from across pharma and MD&D to provide practical services and advisory for our clients, from business assessments and technology implementations to ensuring scalability for large and long term needs.
With hubs in the US and Switzerland, we provide the capacity and expertise of a large consultancy with the agility and personal approach of an agency. We develop solutions that meet the focus and size of each organization we serve — emerging and rare disease pharma to generics manufacturers and mid-tier and large pharma. Our clients always have our full attention and direct access to senior leadership.
- Deep expertise in pricing, contracting and commercial excellence
- 20+ years of experience in US and European markets
- Teams in the US and Switzerland to support global programs
- Results-driven approach tailored to the unique dynamics impacting our clients
- Continuous record of success with business assessments and technology implementations
US Pricing & Contracting
The US pricing and market access landscape for life sciences manufacturers is evolving in complexity due to continuous innovation, dynamic legislation driving federal and state healthcare programs for patients, and increasing obligations surrounding statutory reporting requirements.
Adding to this complexity, the industry faces ongoing mergers, acquisitions and divestitures among manufacturers, large investments into early molecules and emerging biotech, and exponential increase in technology and data available for manufacturers to support payer, provider and public channels.
At Marbls, we support our clients across emerging biotech, generics, MD&D to large branded pharma addressing this complexity through business and technology consulting. Through advisory and strategic services to support a product launch, large-scale systems implementation of leading revenue management software, or assessment and planning for technology investments, our teams provide expert, practical, customer focused, and results-oriented services to solve each of these challenges.
Our expertise spans Contracting and Government Pricing functions, including:
- Contract Lifecycle Management & Quoting
- Contract Management of Payers and Providers
- Administration of Chargebacks
- Rebates & Admin Fees Management
- Statutory Reporting and Pricing Requirements for Government (Federal and State)
- Management & Adjudication of State Medicaid Programs.
- State Price Transparency Reporting
- Gross to Net Analysis
Global Pricing, Tendering, and Market Access
The global landscape for life sciences manufacturers is rapidly evolving in complexity due to continuous innovation, continued pressure towards reimbursement and access, and ongoing operational complexity surrounding pricing, tendering and in-country net price management. We address these challenges with specific, practical approaches targeted to in-country needs, regional requirements and global governance. Our teams leverage deep experience in key EMEA, Asia-Pac and Latin American markets to provide services in advisory, operations, and technology implementations that create tailored solutions for market access, list price management, tendering, contracting, net price management and more.
We address these challenges with specific, practical approaches targeted to in-country needs, regional requirements and global governance. Our teams leverage deep experience in key EMEA, Asia-Pac and Latin American markets to provide service in advisory, operations and technology planning and implementations that create tailored solutions for market access, list price management, tendering, in-country contracting and net price management, and more.
Pharmaceutical manufacturers have witnessed dramatic changes in the industry’s commercial landscape. The dominant role of oncology as the largest therapeutic area in sales and R&D investments. The increasing role of biologics, gene therapies and digital therapeutics as means of combating disease. And the changing regulatory landscape with increased focus on privacy, compliance and reducing healthcare costs.
Today, smaller target groups with a more complex interplay of stakeholders in the decision-making process require the development of innovative commercial strategies and operating models with technology playing a critical, enabling role.
To add to this list, the Covid-19 pandemic has introduced numerous barriers to implementing commercial strategies for pharmaceutical manufacturers. Limited access to HCPs, shifted treatment priorities and overwhelmed healthcare systems require emerging-biotech and mid-large manufacturers to completely rethink their existing commercial models.
To address this highly complex landscape, our teams support our clients with business and technology consulting within the commercial space. Whether its advisory and strategic services to develop and implement a brand strategy, global commercial system rollout, mobile app development and launch, or planning and assessment for technology investments, our expert teams provide experienced, hands-on and result-oriented service to solve our client’s most complex challenges.
The number of novel drug approvals by both the Food and Drug Administration (FDA) and European Medicines Agency (EMA) has been growing rapidly over the last decade with single year record approvals by the FDA in recent years. Drug approvals and launches stretch across diverse therapeutic areas including orphan and rare disease. Today, emerging pharma and biotech have to meet the complexities of a launch across commercial channels, answer reimbursement pressures in various countries, and address compliance and statutory reporting obligations in diverse markets, such as the United States.
At Marbls, we have a strong focus on helping emerging life sciences manufacturers launch products with readiness towards contracting and government pricing functions such as:
- Contract management of payors and providers
- Administration of chargebacks
- Rebates and admin fees management
- Statutory reporting and pricing requirements for government (federal and state)
- Management and adjudication of state Medicaid programs
- State price transparency reporting
- Gross to Net Analysis
As many companies plan to outsource commercial and government contracting functions to outside providers, Marbls provides services to support assessment, evaluation and recommendation towards chosen providers and a detailed plan and roadmap towards launch readiness. Our teams work as an extension of internal teams to oversee and manage the transition to a chosen outsourcing provider while ensuring key launch dependencies are executed seamlessly across all internal and external stakeholders.
With mobile apps becoming critical to day-to-day productivity, Marbls mobile technologies serve diverse needs for insights, analysis and operations. Our development process translates ideas from drawing board to deployment without large investments in consulting services or technology.
Our apps address traditional functions such as approvals and workflows within an organization as well as advanced pricing and quoting capabilities for Medical Device and Diagnostics field teams and remote support for day-to-day activities for pharmaceutical sales forces, mobile technologies and applications. Our development process supports critical pricing and commercial functions:
- Ability to research, distill and write content for your mobile apps
- Advisory in translating of business requirements into functional design of the mobile app
- Rapid prototyping with a data refresh of the app demonstrated every two weeks
- Training and deployment support for maximum adoption
- End-to-end testing combining manual and automated testing
- Post-go live service and monitoring